key: cord-0702543-ych3f1pm
authors: Ellebedy, Ali; Turner, Jackson; Kim, Wooseob; Kalaidina, Elizaveta; Goss, Charles; Rauseo, Adriana; Schmitz, Aaron; Hansen, Lena; Haile, Alem; Klebert, Michael; Pusic, Iskra; O’Halloran, Jane; Presti, Rachel
title: SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans
date: 2020-12-31
journal: Res Sq
DOI: 10.21203/rs.3.rs-132821/v1
sha: 0508e6b75726f158b7f47ac48b40ebbccfd980e0
doc_id: 702543
cord_uid: ych3f1pm

Infection or vaccination induces a population of long-lived bone marrow plasma cells (BMPCs) that are a persistent and essential source of protective antibodies1–5. Whether this population is induced in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. Recent reports have suggested that SARS-CoV-2 convalescent patients experience a rapid decay in their antigen-specific serum antibodies, raising concerns that humoral immunity against this virus may be short-lived6–8. Here we show that in patients who experienced mild infections (n=73), serum anti-SARS-CoV-2 spike (S) antibodies indeed decline rapidly in the first 3 to 4 months after infection. However, this is followed by a more stable phase between 4- and 8-months after infection with a slower serum anti-S antibody decay rate. The level of serum antibodies correlated with the frequency of S-specific long-lived BMPCs obtained from 18 SARS-CoV-2 convalescent patients 7 to 8 months after infection. S-specific BMPCs were not detected in aspirates from 11 healthy subjects with no history of SARS-CoV-2 infection. Comparable frequencies of BMPCs specific to contemporary influenza virus antigens or tetanus and diphtheria vaccine antigens were present in aspirates in both groups. Circulating memory B cells (MBCs) directed against the S protein were detected in the SARS-CoV-2 convalescent patients but not in uninfected controls, whereas both groups had MBCs against influenza virus hemagglutinin. Overall, we show that robust antigen specific long-lived BMPCs and MBCs are induced after mild SARS-CoV-2 infection of humans.

Reinfections by seasonal coronaviruses occur 6-12 months after the previous infection, 51

indicating that protective immunity against these viruses may be short-lived 9,10 . Early 52 reports documenting rapidly declining antibody titers in convalescent SARS-CoV-2 53 patients in the first several months after infection suggested that protective immunity 54 against SARS-CoV-2 may be similarly transient [6] [7] [8] . It was recently suggested that 55 SARS-CoV-2 infection may fail to elicit a functional germinal center response, interfering 56 with generation of the long-lived plasma cells that maintain durable antibody titers [2] [3] [4] [5] 11 . 57

However, more recent reports analyzing samples collected approximately 4 to 6 months 58 after infection indicate that SARS-CoV-2 antibody titers decline more slowly [12] [13] [14] [15] . 59

Because durable serum antibody titers are maintained by long-lived bone marrow 60 plasma cells (BMPCs), we sought to determine whether they were detectable in SARS-61

CoV-2 convalescent patients approximately 7 months after infection. 62

Blood samples were collected approximately 1 month after onset of symptoms from 65 seventy-three SARS-CoV-2 convalescent volunteers (47.9% female, 52.1% male, 66 median age 49), the majority of whom had experienced mild illness (8.3% hospitalized, 67

Extended Data Table 1 ). Follow-up blood samples were collected twice at 3-month 68 intervals. Additionally, bone marrow aspirates were collected from eighteen of the 69 participants 7 to 8 months after infection and from eleven healthy volunteers with no 70 history of SARS-CoV-2 infection (Fig. 1a , Extended Data Table 2 CoV-2 convalescent participants and were stable over the course of the study (Fig. 1b) . 80

The biphasic decay in anti-S IgG is consistent with a transition of serum antibody titers 83 from being supported by short-lived plasmablasts to a smaller but more persistent 84 population of long-lived plasma cells generated later in the immune response. The 85 majority of this latter population resides in bone marrow 1,2 . To investigate whether 86 SARS-CoV-2 convalescent patients developed a virus specific long-lived BMPC 87 compartment, we examined their bone marrow aspirates obtained 7 to 8 months after 88 infection for anti-SARS-CoV-2 S-specific long-lived BMPCs. BMPCs were magnetically 89 enriched from the aspirates and we then quantified the frequencies of those secreting 90

IgG and IgA directed against the 2019/2020 influenza virus vaccine, tetanus/diphtheria 91 vaccine, and SARS-CoV-2 S protein by ELISpot (Fig. 2a) . Frequencies of influenza and 92 tetanus/diphtheria vaccine specific BMPCs were comparable between control and 93 convalescent participants. IgG-and IgA-secreting S-specific BMPCs were detected in 94 14 and 9 of the 18 convalescent participants, respectively, but not in any of the 11 95 control participants (Fig. 2b) . Importantly, none of the convalescent patients had 96 detectable plasmablasts in blood at the time of bone marrow sampling, indicating that 97 the detected BMPCs represent long-lived, bone marrow resident cells and were not 98 recently generated. Frequencies of anti-S IgG BMPCs showed a modest but significant 99 correlation with circulating IgG titers 7-8 months post symptom onset in convalescent 100 participants, consistent with long-term maintenance of antibody levels by these cells. In 101 accordance with previous reports 16-18 , frequencies of influenza vaccine-specific IgG 102

BMPCs and antibody titers exhibited a strong and significant correlation (Fig. 2c) . plasmablasts generates an early wave of serum antibodies that decline relatively quickly 131 once a peak titer is reached. This is followed by more stably maintained serum antibody 132 titers in those four donors were low, suggesting that S-specific BMPCs may potentially 144 be present at very low frequencies that are below our limit of detection. Another 145 limitation is while SARS-CoV-2 S protein is the main target of neutralizing 146 antibodies 12,19-24 , we do not know the fraction of the S-specific BMPCs detected 7 147 months after infection in our study encoding neutralizing antibodies. It is important to 148 note, however, that correlation between serum anti-S IgG binding and neutralization 149 titers has been documented 12,25 . Further studies will be required to determine the 150 epitopes targeted by BMPCs and MBCs and how preexisting immunity to human 151 coronaviruses could alter the immune response to SARS-CoV-2 infection and 152

immunization. Finally, while our data document a robust induction of long-lived BMPCs 153

after SARS-CoV-2 infection, it is critical to note that our convalescent patients mostly 154 experienced mild infections. Our data are consistent with a recent report showing that 155 individuals who recovered rapidly from symptomatic SARS-CoV-2 infection generated a 156 robust humoral immune response 26 . Therefore, it is possible that more severe SARS-157

CoV-2 infections could lead to a different outcome with respect to long-lived BMPC 158 frequencies due to dysregulated humoral immune responses. This, however, has not Immunol. 46, 1-8 (1981 We thank the generous participation of the donors for providing precious specimens. Table Titles 

Duration of antiviral immunity after smallpox vaccination

Long-Lived Plasma Cells Are Contained within the 189 CD19−CD38hiCD138+ Subset in Human Bone Marrow

The generation of 192 antibody-secreting plasma cells

Clinical and immunological assessment of asymptomatic SARS-194

CoV-2 infections

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with 196 Mild Covid-19

Longitudinal observation and decline of neutralizing antibody 198 responses in the three months following SARS-CoV-2 infection in humans

Seasonal coronavirus protective immunity is short-lasting

The time course of the 203 immune response to experimental coronavirus infection of man

Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal 206 Centers in COVID-19

Persistence of serum and saliva antibody responses to SARS-CoV-2 210 spike antigens in COVID-19 patients

Immunological memory to SARS-CoV-2 assessed for greater than 212 six months after infection

Influenza vaccine-induced human bone marrow plasma cells 218 decline within a year after vaccination

Distribution of Immunoglobulin-containing Cells in Human Bone Marrow 220 and Lymphoid Tissues

Plasma cell numbers decrease in bone marrow of old patients

A human neutralizing antibody targets the receptor binding site of 224 SARS-CoV-2

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by 226

Single-Cell Sequencing of Convalescent Patients' B Cells

Convergent antibody responses to SARS-CoV-2 in 229 convalescent individuals

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-231

Neutralizing Antibodies from COVID-19 Patients

Relevant data are available from the corresponding author upon reasonable request. 415